Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Biophotonic Spectroscopic tool for Helicobacter Pylori diagnosis - a pathway for low cost clinical robotic device

Project description

New device to look for signs of gastric cancer

The sixth most common cause of cancer-related death in Europe, gastric cancer remains difficult to cure. The majority of all gastric cancer cases are attributed to infection from Helicobacter pylori. The infection leads to changes in many factors that are important to the pathogenesis of gastric cancer. However, high costs, ambiguous diagnosis and poor patient engagement with existing diagnostic methods result in late- or advanced-stage diagnosis of this cancer. The EU-funded H. Pylori-Scopy project will address this issue. It will develop a screening device to perform early diagnosis, making it easily accessible, portable, unambiguous and instantaneous. This endoscopic device will work with low-cost robotic control.

Objective

Gastric Cancer (GC) is the fifth most common malignancy in the world. Being the third leading cause of death, it claimed 723,000 lives worldwide in 2012, 12 lives/day in the UK (2014-2016), 29 lives/day in U.S. in 2018 and 6th most common in Europe. With such high number of deaths, it can be compared to no less than an epidemic disease. According to International Agency for Research on Cancer, 89% of all GC cases are attributed to infection from Helicobacter Pylori (Hp). H. pylori produces an enzyme called urease which causes creation of an alkaline buffer zone which keeps it safe from gastric acid and silences the immune system of stomach against this microbe. This result in formation of gastric ulcer which grows into cancerous tumour. Early diagnosis of H. pylori is important for understanding pathology of gastric cancer and starting early therapy. But high cost, ambiguous diagnosis and poor patient engagement of existing diagnostic methods leads to late/advanced stage diagnosis of cancer. Patients spend $700-$1800 for standard 2 week triple drug therapy. Such high cost in low and middle income country (LMIC) is a burden where 33 million individual face catastrophic health expense & cancer take their toll at the cost of human life. This cost can further increase with late diagnosis. H. Pylori-Scopy aims to reduce the cost by performing early diagnosis with single stop, easily accessible, portable, unambiguous, instantaneous screening device, which results in increased patient engagement with no waiting for medical reports and quick medication. H. Pylori-Scopy is a combination of light based Raman/Fourier Transform Infrared, & Chitosan-Magnetic-Swob spectroscopy, which offer an unambiguous addendum tool for h-pylori diagnosis using standard endoscopy, suitable not only for in-theatre but also for portable/accessible use in the LMIC regions. H.Pylori-Scopy integrates all three techniques into an endoscopic device which will work with low-cost robotic control.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF-EF-ST - Standard EF

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2018

See all projects funded under this call

Coordinator

UNIVERSITY OF LEEDS
Net EU contribution
€ 224 933,76
Address
WOODHOUSE LANE
LS2 9JT Leeds
United Kingdom
Region
Yorkshire and the Humber West Yorkshire Leeds
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 224 933,76